Listed in the December 27, 2023 extract; not in the current extract (September 22, 2026): Hydromorph Contin (02125382), Hydromorph Contin (02125390). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-09-22.xml.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Hydromorphone HCL
Form:
24 of 24 products shown
22 general benefit · 2 not a benefit
PMS-HYDROmorphone · DIN 01916386 · 1 mg/mL · Oral Sol
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-HYDROmorphone · DIN 01916386
Manufacturer: Pharmascience Inc.; listing date 2006-01-24
Health Canada: Marketed since 1991-12-31 · brand PMS HYDROMORPHONE SIROP 1MG/ML · ATC N02AA03 HYDROMORPHONE · form Syrup · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG/ML · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-HYDROmorphone: Formulary list price $0.09 per unit (the source does not state the unit; exact figure $0.0931). What the ministry pays, not the patient.
Ministry pays: $0.0931 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 01916386: PMS-HYDROmorphone
Raw flags: sec3=Y
Item: 280808013; group id 406; item number 0975; lccId None; manufacturer id PMS
Source form: Oral Sol; strength: 1mg/mL
Recorded listing: General benefit
Source prices (unrounded): $0.0931; ministry $0.0931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01916386
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11870Interchangeable products
Dilaudid · DIN 00786535 · not recorded
Shortage status: resolved shortage (ended December 6, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01916386
Shortage record checked October 6, 2026
Apo-Hydromorphone · DIN 02364115 · 1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364115
Manufacturer: Apotex Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Apotex inc · schedule Narcotics (cdsa i)
Apo-Hydromorphone: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0959). What the ministry pays, not the patient.
Ministry pays: $0.0959 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02364115: Apo-Hydromorphone
Raw flags: sec3=Y
Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id APX
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0959; ministry $0.0959
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364115
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84905Interchangeable products
Dilaudid · DIN 00705438 · $0.0959
PMS-HYDROmorphone · DIN 00885444 · $0.0959
Teva-Hydromorphone · DIN 02319403 · $0.0959
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364115
Shortage record checked October 6, 2026
Dilaudid · DIN 00705438 · 1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Dilaudid · DIN 00705438
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 2008-12-12 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Purdue pharma · schedule Narcotics (cdsa i)
DIN 00705438: Dilaudid
Raw flags: sec3=Y
Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id PFP
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.1061; ministry $0.0959
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00705438
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6889Interchangeable products
Apo-Hydromorphone · DIN 02364115 · $0.0959
PMS-HYDROmorphone · DIN 00885444 · $0.0959
Teva-Hydromorphone · DIN 02319403 · $0.0959
Shortage status: active shortage (reported September 29, 2026, estimated to end October 12, 2026, last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00705438
Shortage record checked October 6, 2026
PMS-HYDROmorphone · DIN 00885444 · 1 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885444
Manufacturer: Pharmascience Inc.; listing date 2001-10-11
Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 1MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-HYDROmorphone: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0959). What the ministry pays, not the patient.
Ministry pays: $0.0959 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00885444: PMS-HYDROmorphone
Raw flags: sec3=Y
Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id PMS
Source form: Tab; strength: 1mg
Recorded listing: General benefit
Source prices (unrounded): $0.0959; ministry $0.0959
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885444
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11413Interchangeable products
Apo-Hydromorphone · DIN 02364115 · $0.0959
Dilaudid · DIN 00705438 · $0.0959
Teva-Hydromorphone · DIN 02319403 · $0.0959
Shortage status: resolved shortage (ended August 7, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00885444
Hydromorphone: Formulary list price $1.78 per unit (the source does not state the unit; exact figure $1.7830). What the ministry pays, not the patient.
Ministry pays: $1.7830 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02145901: Hydromorphone
Raw flags: sec3=Y
Item: 280808014; group id 406; item number 0973; lccId None; manufacturer id SDZ
Source form: Inj Sol-1mL Pk; strength: 2mg/mL
Recorded listing: General benefit
Source prices (unrounded): $1.7830; ministry $1.7830
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02145901
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18315Interchangeable products
Dilaudid · DIN 00627100 · not recorded
Shortage status: resolved shortage (ended January 31, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02145901
Shortage record checked October 6, 2026
Apo-Hydromorphone · DIN 02364123 · 2 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364123
Manufacturer: Apotex Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG · company Apotex inc · schedule Narcotics (cdsa i)
Apo-Hydromorphone: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1417). What the ministry pays, not the patient.
Ministry pays: $0.1417 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02364123: Apo-Hydromorphone
Raw flags: sec3=Y
Item: 280808018; group id 406; item number 0977; lccId None; manufacturer id APX
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.1417; ministry $0.1417
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364123
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84906Interchangeable products
Dilaudid · DIN 00125083 · $0.1417
PMS-HYDROmorphone · DIN 00885436 · $0.1417
Teva-Hydromorphone · DIN 02319411 · $0.1417
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364123
Shortage record checked October 6, 2026
Dilaudid · DIN 00125083 · 2 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Dilaudid · DIN 00125083
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 2009-01-21 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG · company Purdue pharma · schedule Narcotics (cdsa i)
DIN 00125083: Dilaudid
Raw flags: sec3=Y
Item: 280808018; group id 406; item number 0977; lccId None; manufacturer id PFP
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.1565; ministry $0.1417
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00125083
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5939Interchangeable products
Apo-Hydromorphone · DIN 02364123 · $0.1417
PMS-HYDROmorphone · DIN 00885436 · $0.1417
Teva-Hydromorphone · DIN 02319411 · $0.1417
Shortage status: active shortage (reported August 10, 2026, estimated to end October 12, 2026, last updated September 30, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00125083
Shortage record checked October 6, 2026
PMS-HYDROmorphone · DIN 00885436 · 2 mg · tablet
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885436
Manufacturer: Pharmascience Inc.; listing date 1997-04-10
Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 2MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG · company Perfecta products inc. · schedule Narcotics (cdsa i)
PMS-HYDROmorphone: Formulary list price $0.14 per unit (the source does not state the unit; exact figure $0.1417). What the ministry pays, not the patient.
Ministry pays: $0.1417 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00885436: PMS-HYDROmorphone
Raw flags: sec3=Y
Item: 280808018; group id 406; item number 0977; lccId None; manufacturer id PMS
Source form: Tab; strength: 2mg
Recorded listing: General benefit
Source prices (unrounded): $0.1417; ministry $0.1417
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885436
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11428Interchangeable products
Apo-Hydromorphone · DIN 02364123 · $0.1417
Dilaudid · DIN 00125083 · $0.1417
Teva-Hydromorphone · DIN 02319411 · $0.1417
Shortage status: resolved shortage (ended August 5, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00885436
Hydromorph Contin: Formulary list price $0.81 per unit (the source does not state the unit; exact figure $0.8080). What the ministry pays, not the patient.
Ministry pays: $0.8080 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02125323: Hydromorph Contin
Raw flags: sec3=Y
Item: 280808097; group id 406; item number 0969; lccId None; manufacturer id PFP
Source form: CR Cap; strength: 3mg
Recorded listing: General benefit
Source prices (unrounded): $0.8080; ministry $0.8080
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02125323
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18556
Shortage status: resolved shortage (ended July 22, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02125323
Shortage record checked October 6, 2026
Apo-Hydromorphone · DIN 02364131 · 4 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364131
Manufacturer: Apotex Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4 MG · company Apotex inc · schedule Narcotics (cdsa i)
Apo-Hydromorphone: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2240). What the ministry pays, not the patient.
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02364131: Apo-Hydromorphone
Raw flags: sec3=Y
Item: 280808019; group id 406; item number 0978; lccId None; manufacturer id APX
Source form: Tab; strength: 4mg
Recorded listing: General benefit
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364131
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84907Interchangeable products
Dilaudid · DIN 00125121 · $0.2240
PMS-HYDROmorphone · DIN 00885401 · $0.2240
Teva-Hydromorphone · DIN 02319438 · $0.2240
Shortage status: resolved shortage (ended September 24, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364131
Shortage record checked October 6, 2026
Dilaudid · DIN 00125121 · 4 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Dilaudid · DIN 00125121
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 2008-12-29 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4 MG · company Purdue pharma · schedule Narcotics (cdsa i)
DIN 00125121: Dilaudid
Raw flags: sec3=Y
Item: 280808019; group id 406; item number 0978; lccId None; manufacturer id PFP
Source form: Tab; strength: 4mg
Recorded listing: General benefit
Source prices (unrounded): $0.2469; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00125121
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5940Interchangeable products
Apo-Hydromorphone · DIN 02364131 · $0.2240
PMS-HYDROmorphone · DIN 00885401 · $0.2240
Teva-Hydromorphone · DIN 02319438 · $0.2240
Shortage status: resolved shortage (ended September 1, 2021); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00125121
Shortage record checked October 6, 2026
PMS-HYDROmorphone · DIN 00885401 · 4 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885401
Manufacturer: Pharmascience Inc.; listing date 1999-04-15
Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 4MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 4 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-HYDROmorphone: Formulary list price $0.22 per unit (the source does not state the unit; exact figure $0.2240). What the ministry pays, not the patient.
Ministry pays: $0.2240 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00885401: PMS-HYDROmorphone
Raw flags: sec3=Y
Item: 280808019; group id 406; item number 0978; lccId None; manufacturer id PMS
Source form: Tab; strength: 4mg
Recorded listing: General benefit
Source prices (unrounded): $0.2240; ministry $0.2240
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885401
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11425Interchangeable products
Apo-Hydromorphone · DIN 02364131 · $0.2240
Dilaudid · DIN 00125121 · $0.2240
Teva-Hydromorphone · DIN 02319438 · $0.2240
Shortage status: resolved shortage (ended July 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00885401
Hydromorph Contin: Formulary list price $0.97 per unit (the source does not state the unit; exact figure $0.9749). What the ministry pays, not the patient.
Ministry pays: $0.9749 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02359502: Hydromorph Contin
Raw flags: sec3=Y
Item: 280808306; group id 406; item number 0967; lccId None; manufacturer id PFP
Source form: CR Cap; strength: 4.5mg
Recorded listing: General benefit
Source prices (unrounded): $0.9749; ministry $0.9749
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359502
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84452
Shortage status: resolved shortage (ended August 25, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02359502
Hydromorph Contin: Formulary list price $1.21 per unit (the source does not state the unit; exact figure $1.2072). What the ministry pays, not the patient.
Ministry pays: $1.2072 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02125331: Hydromorph Contin
Raw flags: sec3=Y
Item: 280808098; group id 406; item number 0970; lccId None; manufacturer id PFP
Source form: CR Cap; strength: 6mg
Recorded listing: General benefit
Source prices (unrounded): $1.2072; ministry $1.2072
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02125331
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18558
Shortage status: resolved shortage (ended July 29, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02125331
Shortage record checked October 6, 2026
Apo-Hydromorphone · DIN 02364158 · 8 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Hydromorphone · DIN 02364158
Manufacturer: Apotex Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-12-18 · brand APO-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 8 MG · company Apotex inc · schedule Narcotics (cdsa i)
Apo-Hydromorphone: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3528). What the ministry pays, not the patient.
Ministry pays: $0.3528 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02364158: Apo-Hydromorphone
Raw flags: sec3=Y
Item: 280808020; group id 406; item number 0979; lccId None; manufacturer id APX
Source form: Tab; strength: 8mg
Recorded listing: General benefit
Source prices (unrounded): $0.3528; ministry $0.3528
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02364158
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84908Interchangeable products
Dilaudid · DIN 00786543 · $0.3528
PMS-HYDROmorphone · DIN 00885428 · $0.3528
Teva-Hydromorphone · DIN 02319446 · $0.3528
Shortage status: resolved shortage (ended October 1, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02364158
Shortage record checked October 6, 2026
Dilaudid · DIN 00786543 · 8 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Dilaudid · DIN 00786543
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Marketed since 2008-12-29 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 8 MG · company Purdue pharma · schedule Narcotics (cdsa i)
DIN 00786543: Dilaudid
Raw flags: sec3=Y
Item: 280808020; group id 406; item number 0979; lccId None; manufacturer id PFP
Source form: Tab; strength: 8mg
Recorded listing: General benefit
Source prices (unrounded): $0.3892; ministry $0.3528
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00786543
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9509Interchangeable products
Apo-Hydromorphone · DIN 02364158 · $0.3528
PMS-HYDROmorphone · DIN 00885428 · $0.3528
Teva-Hydromorphone · DIN 02319446 · $0.3528
Shortage status: resolved shortage (ended January 8, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00786543
Shortage record checked October 6, 2026
PMS-HYDROmorphone · DIN 00885428 · 8 mg · tablet
General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-HYDROmorphone · DIN 00885428
Manufacturer: Pharmascience Inc.; listing date 2001-10-11
Health Canada: Marketed since 1991-12-31 · brand PMS-HYDROMORPHONE TAB 8MG · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 8 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-HYDROmorphone: Formulary list price $0.35 per unit (the source does not state the unit; exact figure $0.3528). What the ministry pays, not the patient.
Ministry pays: $0.3528 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 00885428: PMS-HYDROmorphone
Raw flags: sec3=Y
Item: 280808020; group id 406; item number 0979; lccId None; manufacturer id PMS
Source form: Tab; strength: 8mg
Recorded listing: General benefit
Source prices (unrounded): $0.3528; ministry $0.3528
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00885428
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11363Interchangeable products
Apo-Hydromorphone · DIN 02364158 · $0.3528
Dilaudid · DIN 00786543 · $0.3528
Teva-Hydromorphone · DIN 02319446 · $0.3528
Shortage status: resolved shortage (ended July 28, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00885428
Hydromorph Contin: Formulary list price $1.59 per unit (the source does not state the unit; exact figure $1.5928). What the ministry pays, not the patient.
Ministry pays: $1.5928 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02359510: Hydromorph Contin
Raw flags: sec3=Y
Item: 280808307; group id 406; item number 0968; lccId None; manufacturer id PFP
Source form: CR Cap; strength: 9mg
Recorded listing: General benefit
Source prices (unrounded): $1.5928; ministry $1.5928
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02359510
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84453
Shortage status: resolved shortage (ended August 12, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02359510
Hydromorphone HP-10: Formulary list price $4.35 per unit (the source does not state the unit; exact figure $4.3460). What the ministry pays, not the patient.
Ministry pays: $4.3460 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02145928: Hydromorphone HP-10
Raw flags: sec3=Y
Item: 280808015; group id 406; item number 0974; lccId None; manufacturer id SDZ
Source form: Inj Sol-1mL Pk; strength: 10mg/mL
Recorded listing: General benefit
Source prices (unrounded): $4.3460; ministry $4.3460
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02145928
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18323Interchangeable products
Dilaudid-HP · DIN 00622133 · not recorded
Shortage status: resolved shortage (ended August 14, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02145928
Hydromorph Contin: Formulary list price $2.10 per unit (the source does not state the unit; exact figure $2.0990). What the ministry pays, not the patient.
Ministry pays: $2.0990 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02125366: Hydromorph Contin
Raw flags: sec3=Y
Item: 280808099; group id 406; item number 0971; lccId None; manufacturer id PFP
Source form: CR Cap; strength: 12mg
Recorded listing: General benefit
Source prices (unrounded): $2.0990; ministry $2.0990
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02125366
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=20171
Shortage status: resolved shortage (ended June 9, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02125366
Hydromorph Contin: Formulary list price $3.03 per unit (the source does not state the unit; exact figure $3.0285). What the ministry pays, not the patient.
Ministry pays: $3.0285 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
DIN 02243562: Hydromorph Contin
Raw flags: sec3=Y
Item: 280808123; group id 406; item number 0972; lccId None; manufacturer id PFP
Source form: CR Cap; strength: 18mg
Recorded listing: General benefit
Source prices (unrounded): $3.0285; ministry $3.0285
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243562
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67480
Shortage status: resolved shortage (ended September 3, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243562
Shortage record checked October 6, 2026
Teva-Hydromorphone · DIN 02319403 · 1 mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.Discontinued July 30, 2021 · checked November 18, 2026
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-07-30 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Hydromorphone · DIN 02319403
Manufacturer: Teva Canada Limited; listing date 2012-06-26
Health Canada: Cancelled post market since 2021-07-30 · brand TEVA-HYDROMORPHONE · ATC N02AA03 HYDROMORPHONE · form Tablet · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Teva-Hydromorphone: Formulary list price $0.10 per unit (the source does not state the unit; exact figure $0.0959). What the ministry pays, not the patient.
Ministry pays: $0.0959 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02319403).
DIN 02319403: Teva-Hydromorphone
Raw flags: dinStatus=E, sec3=Y
Item: 280808017; group id 406; item number 0976; lccId None; manufacturer id TEV
Source form: Tab; strength: 1mg
Recorded listing: General benefit; DIN status E, meaning unconfirmed
Source prices (unrounded): $0.0959; ministry $0.0959
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02319403
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80489Interchangeable products
Apo-Hydromorphone · DIN 02364115 · $0.0959
Dilaudid · DIN 00705438 · $0.0959
PMS-HYDROmorphone · DIN 00885444 · $0.0959
Shortage status: discontinued (August 31, 2018, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02319403
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 30, 2021 — choose a marketed DIN from the same-category list.
Dilaudid · DIN 00786535 · 1 mg/mL · Oral Sol
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-23 — choose a marketed DIN from the same-category list.Discontinued January 23, 2018 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2018-01-23 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2018-01-23 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Dilaudid · DIN 00786535
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Cancelled post market since 2018-01-23 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Liquid · route Oral · ingredients HYDROMORPHONE HYDROCHLORIDE 1 MG/ML · company Purdue pharma · schedule Narcotics (cdsa i)
DIN 00786535: Dilaudid
Raw flags: notABenefit=Y, sec3=Y
Item: 280808013; group id 406; item number 0975; lccId None; manufacturer id PFP
Source form: Oral Sol; strength: 1mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00786535
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10173Interchangeable products
PMS-HYDROmorphone · DIN 01916386 · $0.0931
Shortage status: discontinued (March 1, 2018, reported by PURDUE PHARMA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00786535
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since January 23, 2018 — choose a marketed DIN from the same-category list.
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-12-05 — choose a marketed DIN from the same-category list.Discontinued December 5, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-12-05 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2023-12-05 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Dilaudid · DIN 00627100
Manufacturer: Purdue Pharma; listing date 1996-10-01
Health Canada: Cancelled post market since 2023-12-05 · brand DILAUDID · ATC N02AA03 HYDROMORPHONE · form Liquid · route Intramuscular, Intravenous, Subcutaneous · ingredients HYDROMORPHONE HYDROCHLORIDE 2 MG/ML · company Purdue pharma · schedule Narcotics (cdsa i)
DIN 00627100: Dilaudid
Raw flags: notABenefit=Y, sec3=Y
Item: 280808014; group id 406; item number 0973; lccId None; manufacturer id PFP
Source form: Inj Sol-1mL Pk; strength: 2mg/mL
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00627100
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=5937Interchangeable products
Hydromorphone · DIN 02145901 · $1.7830
Shortage status: resolved shortage (ended December 31, 2017); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00627100
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since December 5, 2023 — choose a marketed DIN from the same-category list.
Other products in the same Health Canada class (N02A, N02AA): coverage varies; not interchangeable
Morphine (M-Eslon): general benefit, not a benefit
Acetylsalicylic acid + butalbital + caffeine + codeine (Fiorinal C1/4): not a benefit
Oxycodone (Supeudol): not a benefit
Acetaminophen + caffeine + codeine (Teva-Lenoltec No.2): general benefit, not a benefit
Acetaminophen + codeine (PMS-Acetaminophen With Codeine): general benefit, not a benefit
Acetaminophen + oxycodone (Teva-Oxycocet): general benefit, not a benefit
4 more in the class list below
Other drugs in the same formulary class (28:08:08 Opiate Agonists) and how they are covered
Matched class: 28:08:08 Opiate Agonists
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE, ACETAMINOPHEN & CODEINE PHOSPHATE, CODEINE PHOSPHATE, METHADONE HCL, MORPHINE SULFATE, OXYCODONE HCL & ACETAMINOPHEN, OXYCODONE HCL & ACETYLSALICYLIC ACID
28:08:08 Opiate Agonists
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
No displayed matched alternative is a general benefit.
ACETAMINOPHEN & CAFFEINE & CODEINE PHOSPHATE · General benefit (2), Listed, not a benefit (2)
INDICATIONS AND CLINICAL USE
Adults
TEVA-LENOLTEC No. 2 and No. 3 (acetaminophen, caffeine and codeine phosphate) are indicated
for the short-term relief of mild to moderate pain.
PM: https://pdf.hres.ca/dpd_pm/00065848.PDF; date July 15, 2014; DIN 00653241; fetched 2026-09-10
Product monographBUTORPHANOL TARTRATE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
Adults
BUTORPHANOL Nasal Spray (butorphanol tartrate) is indicated for:
• the relief of moderate to severe acute pain.
PM: https://pdf.hres.ca/dpd_pm/00069311.PDF; date MAR 24, 2015; DIN 02242504; fetched 2026-09-10
Product monographCELECOXIB · Limited Use, codes 316, 317
1 INDICATIONS
CELEBREX (celecoxib capsules) is indicated for relief of symptoms associated with:
• Osteoarthritis,
• Adult Rheumatoid Arthritis, and
• Ankylosing Spondylitis
CELEBREX is also indicated for the short-term ( 7 days) management of moderate to severe acute pain
in adults in conditions such as the following:
• Musculoskeletal and/or soft tissue trauma including sprains,
• Postoperative orthopaedic, and
• Pain following dental extraction
CELEBREX, particularly at doses higher than 200 mg per day, is associated with an increased risk of
serious cardiovascular related adverse events (such as myocardial infarction, stroke or thrombotic
events), which can be fatal.
PM: https://pdf.hres.ca/dpd_pm/00080998.PDF; date 2025-07-09; DIN 02239941; fetched 2026-09-10
Product monographCODEINE SULFATE TRIHYDRATE & MONOHYDRATE · Limited Use, codes 201
1 Indications
CODEINE CONTIN (codeine controlled release tablets) is indicated for the relief of mild to
moderate pain in adults requiring the prolonged use of an opioid analgesic preparation.
PM: https://pdf.hres.ca/dpd_pm/00078791.PDF; date 2025-03-04; DIN 02163748; fetched 2026-09-10
Product monographOXYCODONE HCL · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
Supeudol® 5 (oxycodone hydrochloride tablets) / Supeudol® 10 (oxycodone hydrochloride
tablets) is indicated for:
• relief of moderate to severe pain.
PM: https://pdf.hres.ca/dpd_pm/00080231.PDF; date not captured; DIN 00443948; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS
DILAUDID® (HYDROmorphone hydrochloride) is indicated for the relief of moderate to severe pain in
adults.
1.1 Pediatrics
No data are available to Health Canada. Therefore, Health Canada has not authorized an indication for
pediatric use.
1.2 Geriatrics
In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the
dosing range, and titrated slowly, reflecting the greater frequency of decreased hepatic, renal or cardiac
function, concomitant disease or other drug therapy (see 7.1.4 Geriatrics).
https://pdf.hres.ca/dpd_pm/00072218.PDF
PM date: August 29, 2023
Source product: DILAUDID; DIN 00125083; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Dilaudid · DIN 00705438
Shortage status: active shortage (reported 2026-09-29, estimated to end 2026-10-12, last updated 2026-09-30); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00705438
Dilaudid · DIN 00125083
Shortage status: active shortage (reported 2026-08-10, estimated to end 2026-10-12, last updated 2026-09-30); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00125083
Teva-Hydromorphone · DIN 02319403
Shortage status: discontinued (2018-08-31, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02319403
Dilaudid · DIN 00786535
Shortage status: discontinued (2018-03-01, reported by PURDUE PHARMA); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00786535
For Dilaudid: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.